Merck & Co., Inc. Stock Swiss Exchange

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Swiss Exchange 11:36:38 2022-12-05 am EST 5-day change 1st Jan Change
400 CHF +388.82% Intraday chart for Merck & Co., Inc. -.--% -.--%
Sales 2024 * 64.18B 57.18B Sales 2025 * 68.68B 61.19B Capitalization 328B 292B
Net income 2024 * 19.51B 17.38B Net income 2025 * 22.25B 19.82B EV / Sales 2024 * 5.4 x
Net Debt 2024 * 18.6B 16.57B Net Debt 2025 * 7.28B 6.49B EV / Sales 2025 * 4.88 x
P/E ratio 2024 *
16.7 x
P/E ratio 2025 *
14.5 x
Employees -
Yield 2024 *
2.39%
Yield 2025 *
2.53%
Free-Float 70.77%
More Fundamentals * Assessed data
Dynamic Chart
5 years
72.85
Extreme 72.85
400.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.5 USD
Average target price
142.7 USD
Spread / Average Target
+10.20%
Consensus